Spyros Papapetropoulos left the role of Director at Lipocine Inc. As of November 6, 2026, Lipocine Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to August 3, 2026, naming 2 departures (Form 8-K, April 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Lipocine Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Lipocine Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-08-03. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Lipocine Inc. files it.
Also on the record for Lipocine Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 9.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Ikarian Capital, LLC | 6.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 6.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Squadron Master Fund LP | 9.5% of the class | 5%+ stakes | Source |
| December 23, 2025 | Stake report, Schedule 13G, by Squadron Capital Management LLC | 9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Lipocine Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Lipocine Inc. and the records around it.
Lipocine Inc. elsewhere on the record
Companies that share a holder
- Squadron Master Fund LP also filed stake reports on 14 other companies: Contineum Therapeutics, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), C4 Therapeutics, Inc. (Aug 2026)
- Ikarian Capital, LLC also filed stake reports on 22 other companies: Quoin Pharmaceuticals Ltd. (Oct 2026), Connect Biopharma Holdings Limited (Aug 2026), Galera Therapeutics, Inc. (Aug 2026)
Watch Lipocine Inc.
Get an email when Lipocine Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lipocine Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Lipocine Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lipocine Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-03 | Reported | not named in the filing | 8-K, 2026-08-03 | ||
| 2026-04-21 | Out | Director | 8-K, 2026-04-21 | ||
| 2026-04-21 | Out | 8-K, 2026-04-21 |
Who leads Lipocine Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Spyros Papapetropoulos, departure reported (filed 2026-04-21). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Lipocine Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Lipocine Inc., with the record behind each one.
Find candidates like Director at Lipocine Inc.Every change, in the filing's words
Reported
Mr. Grissinger will serve until the election of directors at the next annual meeting of the Company's stockholders or until his earlier death, disqualification, resignation or removal.
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offices Appointment of Michael Grissinger as a Director On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.
- The Board of Directors has determined that Mr. Grissinger is an independent director under the listing standards of the Nasdaq Stock Market.
- In connection with his appointment as a member of the Board of Directors, Mr. Grissinger will receive an initial stock option grant to purchase 2,000 shares of common stock of the Company.
- In addition, as a non-employee director he will receive an annual retainer of $55,000 per year.
Departing: Spyros Papapetropoulos, Director
On April 16, 2026, Spyros Papapetropoulos informed the Board of Directors (the "Board") of Lipocine Inc. (the "Company") that he resigned as a member of the Board effective immediately.
Departing: Spyros Papapetropoulos
Dr. Papapetropoulos resigned due to competing professional commitments and evolving board dynamics arising from differing views on the Company's strategic direction.
- Dr. Papapetropoulos has served as a member of the Board since 2022 and was the Board's Chairman and Lead Independent Director and a member of the Board's compensation committee.
- On April 20, 2026, the Board appointed R. Dana Ono as Chairman of the Board and Lead Independent Director.
Tools for this story
Each opens in a new tab, filled in for Lipocine Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.